Drug intelligence / Profile preview

J4

Development stage: Phase 1
Modality: Small Molecules
Administration: Oral

Overview

J4 is a small molecule compound designed to modulate nucleoside homeostasis by interacting with the equilibrative nucleoside transporter-1 (ENT1). Preclinical studies have shown that oral administration of J4 can rescue memory and cognitive dysfunction in animal models of Alzheimer's disease. Its mechanism involves increasing brain nucleoside levels and facilitating brain primary metabolism, including glucose metabolism and the pentose phosphate pathway.

Targets

ADORA2A (Adenosine A₂A Receptor)ENT1 (Solute carrier family 29 member 1)

Beyond the preview

Go deeper on J4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on J4.

Explore the full profile